发明名称 THERAPEUTIC BINDING MOLECULES
摘要 <p>A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-IIe-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro~Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe -L ys- Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly - Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1', CDR2' and CDR3', CDR1' having the amino aci d sequence Arg-Ala-Ser-Gln-Asn-Ile-GIy-Thr~Ser-IIe-Gln (RASQNIGTSIQ), CDR2' having the amino acid sequence Ser-Ser-Ser-Glu-Ser~Ile-Ser (SSSESIS) and CDR 3' having the amino acid sequence Gln-GIn-Ser-Asn-Thr-Trp~ Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutic al.</p>
申请公布号 CA2537217(A1) 申请公布日期 2005.03.24
申请号 CA20042537217 申请日期 2004.09.17
申请人 NOVARTIS AG 发明人 RONCAROLO, MARIA GRAZIA;KOLBINGER, FRANK;JESCHKE, MARGIT;CARBALLIDO HERRERA, JOSE M.;SALDANHA, JOSE W.;HALL, BRUCE M.;ASZODI, ANDRAS;LOUX, VERONIQUE;AVERSA, GREGORIO;GREGORI, SILVIA
分类号 C07K16/28;A61K39/395;A61P37/00;C12N5/10;C12N15/13;C12N15/62;C12N15/79 主分类号 C07K16/28
代理机构 代理人
主权项
地址